Skip to search formSkip to main contentSkip to account menu

bexarotene

Known as: 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, 3-methyl TTNEB, P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid 
A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties. Bexarotene selectively binds… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (2)

Anticarcinogenic AgentsTetrahydronaphthalenes
Drug AllergyLymphoma, T-Cell, CutaneousNCIt Antineoplastic Agent TerminologyPregnancy

Narrower (2)

LGD 1069Targretin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Retinoidy v dermatologii
Autoři předkladaji historii vývoje a klasifikaci retinoidů, věnuji se jejich farmakodynamickým vlastnostem vcetně biologickeho… 
2012
2012
Treatment of primary cutaneous lymphoma with referen ce to the latest therapeutic consensus of the Polish Lympho ma Research Group (PLRG)
Introduction: Primary cutaneous lymphomas are a heterogeneous collection of lymphoproliferative malignancies with a wide-ranging… 
2012
2012
Successful treatment of a folliculotropic mycosis fungoides with bexarotene and PUVA.
ejd.2011.1632 Auteur(s) : Anna Kronke, Max Schlaak, Meral Arin, Cornelia Mauch, Peter Kurschat peter.kurschat@uk-koeln.de… 
2009
2009
Demographic and Clinical Features of Mycosis Fungoides in Tabriz, Iran
5% of patients with mycosis fungoides are in childhood and adolescence period. 5 The most common skin lesions of mycosis… 
Review
2008
Review
2008
Long term Complete Response to Bexarotene, Photopheresis and Ampicillin
Madeleine Duvic, MD, is Professor of Internal Medicine and Dermatology, and Deputy Chairman of the Department of Dermatology at… 
2008
2008
Tratamiento del linfoma cutáneo de células T con bexaroteno a dosis bajas en combinación con fototerapia o interferon alfa: comunicación de ocho casos tratados en el Hospital Edgardo Rebagliati…
RESUMEN Introduccion: bexaroteno es un rexinoide aprobado en el tratamiento de estadios tempranos y avanzados del linfoma cutaneo… 
2008
2008
A phase II clinical and PET study of erlotinib and bexarotene for heavily pretreated advanced non-small cell lung cancer (NSCLC)
19079 Background: We previously reported a phase I trial of the EGFR tyrosine kinase inhibitor, erlotinib (E), and the… 
2006
2006
Une étiologie d’hypothyroïdie à ne pas méconnaître : l’hypothyroïdie centrale associée au traitement par bexarotène (Targretin ® )
Nous rapportons le cas d’une patiente atteinte d’un lymphome cutane T epidermotrope de type Sezary traitee par bexarotene… 
Review
2005
Review
2005
Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A
and outcome. Among the three patients with a second atypical BM, one died 1 year later due to septicaemia but without progression… 
2000
2000
Bexarotene (Targretin) for cutaneous T-cell lymphoma.